Merck Serono takes option on resurrected T cell therapy for MS
This article was originally published in Scrip
Executive Summary
Merck Serono has obtained an option from Opexa for $5 million for an exclusive license to develop and commercialize Tcelna (imilecleucel-T), a potential first-in-class personalized T cell therapy for patients suffering from multiple sclerosis (MS). With Opexa embarking on an expanded clinical program, this may represent the start of the resurrection for Tcelna, an agent that only a few years ago seemed clinically dead and buried.